Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of remimazolam + remifentanil for moderate sedation gastroscopy in obese adults
ChiCTR2300070089Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: MOAA/S score at 1 minute after induction. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ChiCTR2300070089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070089.